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Abstract Guillain-Barre´ syndrome (GBS) is an acute
demyelinating polyradiculoneuropathy normally associated
with a preceding infection, but sometimes it can be linked
to a subjacent malignancy. We report an unusual case of
GBS occurring as the first clinical manifestation of an
esophageal adenocarcinoma in a 65-year-old patient. A
GBS neuropathy of undetermined origin may be associated
with an underlying tumor and esophageal cancer has to be
considered in the differential diagnosis.
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Introduction
Guillain-Barre´ syndrome (GBS) is an acute inflammatory,
demyelinating peripheral polyneuropathy characterized by
a rapidly ascending muscle weakness or paralysis accom-
panied by absent or depressed deep tendon reflexes and, in
some cases, by respiratory distress. Abnormal immune
response through both humoral and cell-mediated mecha-
nisms is the proposed etiopathogenesis to explain GBS [1].
Most cases of GBS, are preceded by respiratory or gas-
trointestinal infections or immunization, but GBS has also
been linked to malignancies as a possible paraneoplastic
complication. Lymphomas [2], breast [3], small cell lung
[3, 4], and renal carcinomas [5], are the most frequent
tumors associated with GBS. On the other hand, the link
between GBS and esophageal carcinoma is less commonly
found and only few cases are reported in literature. We
describe here the case of a 65-year-old man presenting a
GBS 2 months before the diagnosis of an esophageal
adenocarcinoma.
Case report
A 65-year-old man with history of alcohol and smoke
abuse, presented with an initial numbness of the feet, fol-
lowed by a progressive lower limbs weakness, difficulty to
walk, and impossibility to remain fully ambulant. The
patient had no back pain, headaches or preceding history of
infection or illness. Physical examination revealed a sym-
metrical bilateral weakness in knee flexion and extension,
associated with a deficit in the plantar and dorsal flexion of
the feet. Pallesthesia alteration and pinprick sensation loss
were found below the T-11 dermatome. Reflexes were
absent in the lower limbs, without sphincterial muscles
involvement. Cranial nerves, cerebellar and higher func-
tions examinations were normal. A tendency to postural
hypotension was found.
A lumbar puncture performed 2 days later demonstrated
a raised cerebrospinal fluid (CSF) protein concentration of
1.79 g/L. CSF biochemistry, cytology, cell counts, and
culture as well as the routine hematology, the electrolytes
and the liver function tests were normal. Spinal compres-
sion or acute transverse myelitis was excluded by a mag-
netic resonance imaging of the whole spinal cord. Clinical
neurophysiological studies showed evidence of an acute
polyradiculopathy with reduced motor conduction veloci-
ties and prolonged distal latencies. On the basis of the
clinical presentation, CSF and neurophysiological studies
findings, the diagnosis of GBS was evoked. A treatment of
human intravenous immunoglobulin at standard doses was,
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therefore, administered permitting a partial improvement in
the motor function of the lower limbs without recovery in
the ability to walk.
Negative history for a previous gastrointestinal or
respiratory infection or another triggering event such as
immunization, surgery, trauma or bone-marrow transplan-
tation, suggested the differential diagnosis of a possible
paraneoplastic syndrome. First radiological assessments with
the total body computed tomography did not show any
tumoral lesion explaining the GBS. 2 months later, the patient
started to develop a progressive dysphagia for solids. Eso-
phagogastroduodenoscopy revealed an obstructive, circum-
ferential lesion in the lower third of the esophagus, positive at
biopsy for an adenocarcinoma. [18F]-Fluorodeoxyglucose-
positron emission tomography (FDG-PET/CT) showed a
local disease with sub-diaphragmatic extension to the car-
dia without distant metastasis and esophageal endoscopic
ultrasonography permitted ultimately to stage the lesion as
T3N1. A preoperative treatment of induction chemotherapy
followed by chemoradiation as proposed in the Swiss
multicenter SAKK 75/02 protocol was, therefore started
[6]. After the induction chemotherapy consisting of doce-
taxel (75 mg/m2) and cisplatin (75 mg/m2) on days 1 and
22, the patient presented a good metabolic response at the
FDG-PET/CT with a standardized uptake value (SUV) that
diminished from 14.5 at the diagnosis to 5.6. This treatment
was followed by a radiotherapy to 45 Gy (25 9 1.8 Gy) and
by a concurrent weekly chemotherapy comprising docetaxel
(20 mg/m2) and cisplatin (25 mg/m2) that was administered
only two times and successively interrupted as a conse-
quence of the important hemato-toxicity. Due to the surgical
inoperability of the lesion and to the high comorbidities of
the patient, the decision to deliver an exclusive radiotherapy
treatment to a total dose of 61 Gy was taken.
At the end of the treatment, we assisted at a good
clinical improvement in the neurological status of the
patient with a full functional recovery in the ability to
mobilize independently and in a routine control after
6 months the patient presented no evidence of persistent
esophageal disease. However, 21 months later, a local
symptomatic recurrence was diagnosed and a palliative
attitude with an esophageal stent placement was adopted.
The clinical neurological status continued to be normal.
Discussion
Paraneoplastic neurological syndromes represent a clinical
entity extremely rare in cancer patients with an estimated
incidence rate of about 7% [7]. When a neurological
disorder is reported as a paraneoplastic disease, it is man-
datory to find the direct correlation between the malig-
nancy and the neuropathy. The commonly proposed criteria
used to define a paraneoplastic disease are based on the
increased incidence of a specific cancer in a population
affected by a particular neurological disorder, the short
latency between the onset of the neuropathy and the cancer,
the presence of specific onco-neural antibodies directed
against antigens expressed by the tumor and the nervous
system cells and the absence of other causes explaining the
pathogenesis of the neuropathy [8, 9].
The association between malignancies and GBS is still
controversial and the existence of a paraneoplastic GBS is
not completely accepted. However, different tumor types
such as Hodgkin’s lymphomas, small cell lung carcinoma,
breast, and renal cancer [2–5] have been linked with GBS.
Rare associations are even been reported for T cell non-
Hodgkin’s lymphoma [10], endometrial cancer [11], gall
bladder carcinoma [12] or after autologous, and allogenic
bone marrow transplantations [13, 14]. In a population-
based study of 435 GBS patients, Vigliani et al. [15] found that
the incidence of cancers within 6 months before or after GBS
was significantly greater than normally expected. These
authors stated consequently that a possible pathogenetic
relationship between cancer and some cases of GBS could
exist, fulfilling sometimes the criteria necessary to define this
association as a paraneoplastic phenomenon.
Esophageal cancer has been rarely associated with
neurological syndromes and only one case describing its
relationship with GBS has been reported in the literature
[15]. Our case documents a GBS occurring in a patient as
first clinical manifestation of an esophageal adenocarci-
noma diagnosed 2 months after the onset of the neuro-
logical disorder.
In our patient, the progressive neurological symptoms
onset, the increased protein concentration in CSF and the
electrodiagnostic signs of demyelinization fulfill the com-
monly used criteria for GBS diagnosis. Exclusion of the
common triggering events for GBS and the short latency
between the beginning of the neuropathy and the diagnosis
of the esophageal cancer, evokes a potential pathogenetic
relationship between the two diseases and could suggest a
possible paraneoplastic nature of the GBS. Moreover, the
different timing in the clinical onset of GBS and cancer
observed in our patient may contribute to eliminate sup-
plementary bias related to the cancer therapy. In several
case reports, the GBS in cancer patients was related to the
oncological treatment, especially when chemotherapy
agents containing platinum were used [11, 16]. The
immunosuppressive status induced in these cases by
the treatment could have confounded the real action of the
malignancy in the development of GBS by enhancing the
immunologic-mediated myelin damage catalyzed normally
by the tumor epitope.
However, applying more restrictive criteria to define a
paraneoplastic syndrome [8], our conclusions may become
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more uncertain. Differing from other neurological syn-
dromes, which usually are associated with cancers
expressing onco-neural antibodies, in tumor associated-
GBS there do not exist a specific serological profile to be
used in clinical practice in order to characterize this rela-
tionship [11, 15]. Furthermore, despite a first clinical
improvement, the two diseases had thereafter an indepen-
dent evolution with the recurrence of esophageal cancer
and the stability of the neurological disorder. Based on
these more conservative considerations, in our patient the
association between GBS and cancer could alternatively be
considered as merely casual.
In conclusion, we document with this case report the
rare association existing between an esophageal adeno-
carcinoma and a GBS. The nature of this relationship
remains nevertheless unclear and the real existence of a
paraneoplastic GBS remains still unconfirmed.
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